SKB103 for HER2-negative breast cancer after standard treatment
Part of Cancer, Skin clinical trials.
This trial tests a new drug, SKB103, for people with HER2-negative breast cancer that has not responded to standard treatments. It aims to see if the drug is safe and effective in shrinking tumors or slowing the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have HER2-negative breast cancer that has gotten worse after standard treatments.
- You have at least one measurable tumor.
- You are generally able to take care of yourself (ECOG score 0 or 1).
- Your organs (like liver, kidneys, and bone marrow) are working well enough to receive the drug.
- You are not pregnant, breastfeeding, and agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This trial compares a new experimental drug, JSKN003, to standard treatments chosen by your doctor for advanced breast cancer that tests as HER2-low (IHC 1+ or 2+ but not amplified). It's for people whose cancer has spread or can't be removed and who have already had one or two lines of chemotherapy.
This trial tests a new drug called SKB103 for people with advanced solid tumors that have not responded to standard treatments or who cannot tolerate them. The study aims to see if SKB103 is safe and effective.
This study is a real-world treatment trial for people with advanced HER2-negative breast cancer (either triple-negative or HR+/HER2-). It tests a drug called SKB264, given alone or with other therapies, and aims to see how well it works in everyday clinical practice.
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
This trial tests a new drug called SKB105 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.